3/17
06:52 am
oprx
OptimizeRx (OPRX) was upgraded by Zacks Research from "hold" to "strong-buy".
Low
Report
OptimizeRx (OPRX) was upgraded by Zacks Research from "hold" to "strong-buy".
3/10
10:15 am
oprx
OptimizeRx: Q4 Earnings Report Indicates Caution For 2026 [Seeking Alpha]
Neutral
Report
OptimizeRx: Q4 Earnings Report Indicates Caution For 2026 [Seeking Alpha]
3/6
07:03 pm
oprx
OptimizeRx Corp (OPRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
Low
Report
OptimizeRx Corp (OPRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
3/6
03:52 pm
oprx
OptimizeRx (OPRX) had its price target lowered by Lake Street Capital from $24.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
OptimizeRx (OPRX) had its price target lowered by Lake Street Capital from $24.00 to $20.00. They now have a "buy" rating on the stock.
3/6
12:59 pm
oprx
OptimizeRx (OPRX) had its price target lowered by Roth Mkm from $32.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
OptimizeRx (OPRX) had its price target lowered by Roth Mkm from $32.00 to $18.00. They now have a "buy" rating on the stock.
3/6
12:25 pm
oprx
OptimizeRx (OPRX) had its "buy" rating reaffirmed by B. Riley Financial, Inc.. They now have a $11.00 price target on the stock, down from $28.00.
Medium
Report
OptimizeRx (OPRX) had its "buy" rating reaffirmed by B. Riley Financial, Inc.. They now have a $11.00 price target on the stock, down from $28.00.
3/6
10:59 am
oprx
OptimizeRx (OPRX) had its price target lowered by Stephens from $17.00 to $10.00. They now have an "equal weight" rating on the stock.
Medium
Report
OptimizeRx (OPRX) had its price target lowered by Stephens from $17.00 to $10.00. They now have an "equal weight" rating on the stock.
3/6
10:11 am
oprx
OptimizeRx (OPRX) was given a new $17.00 price target by Stifel Nicolaus.
Medium
Report
OptimizeRx (OPRX) was given a new $17.00 price target by Stifel Nicolaus.
3/5
11:21 pm
oprx
OptimizeRx Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
OptimizeRx Q4 Earnings Call Highlights [Yahoo! Finance]
3/5
10:17 pm
oprx
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates [Yahoo! Finance]
High
Report
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates [Yahoo! Finance]
3/5
06:50 pm
oprx
OptimizeRx Corporation (OPRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
OptimizeRx Corporation (OPRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/5
05:04 pm
oprx
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
High
Report
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
3/5
04:31 pm
oprx
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
High
Report
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/5
04:01 pm
oprx
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
High
Report
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
3/5
01:36 am
oprx
OptimizeRx Q4 2025 Earnings Preview [Seeking Alpha]
Medium
Report
OptimizeRx Q4 2025 Earnings Preview [Seeking Alpha]
2/5
08:00 am
oprx
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
Medium
Report
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
1/8
02:21 pm
oprx
OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades [Yahoo! Finance]
Low
Report
OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades [Yahoo! Finance]
1/7
08:00 am
oprx
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
Medium
Report
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
12/23
10:05 am
oprx
OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story [Seeking Alpha]
Low
Report
OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story [Seeking Alpha]